Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.68 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.68 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17746737 | 0.98 | CYP4F2 (0.66) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL17746731 | 0.98 | CYP4F2 (0.71) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL17746745 | 0.98 | CYP4F2 (0.71) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL20371022 | 0.96 | CYP4F2 (0.69) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL17756700 | 0.95 | CYP4F2 (0.62) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL5524053 | 0.94 | CYP4F2 (0.65) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL17756696 | 0.93 | CYP4F2 (0.60) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL22016457 | 0.93 | CYP4F2 (0.65) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL2985354 | 0.93 | CYP4F2 (0.60) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL6260156 | 0.92 | CYP4F2 (0.62) | CYP4F2CYP4A11PKMTHRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0820428-B1 | TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS | WARNER LAMBERT CO (US) | 2000-05-10 | — | — | EP | claimed |
| EP-0820428-A1 | TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS | WARNER-LAMBERT COMPANY (US) | 1998-01-28 | — | — | EP | claimed |
| US-5648387-A | Carboxyalkylethers, formulations, and treatment of vascular diseases | WARNER-LAMBERT COMPANY (US) | 1997-07-15 | — | — | US | claimed |
| WO-1996030328-A1 | TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS | WARNER-LAMBERT COMPANY (US) | 1996-10-03 | — | — | WO | claimed |
| US-20220402854-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKENE ETHERS | NEUROBO PHARMACEUTICALS INC (US) | 2022-12-22 | — | — | US | disclosed |
| US-20220402854-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKENE ETHERS | NEUROBO PHARMACEUTICALS INC (US) | 2022-12-22 | — | — | US | disclosed |
| CN-111704543-A | Process and intermediates for preparing alpha, omega-dicarboxylic acid terminated dialkyl ethers | 燿石治疗公司 | 2020-09-25 | — | — | CN | disclosed |
| EP-3653598-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING , -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | Gemphire Therapeutics Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3653598-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING , -DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | Gemphire Therapeutics Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| US-20200048181-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | NEUROBO PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-20200048181-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | NEUROBO PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| US-10227285-B2 | Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers | GEMPHIRE THERAPEUTICS INC. (US) | 2019-03-12 | — | — | US | disclosed |
| WO-2000059855-A1 | ETHER COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ESPERION THERAPEUTICS, INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-0820428-B1 | TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS | WARNER LAMBERT CO (US) | 2000-05-10 | — | — | EP | disclosed |
| US-5783600-A | FOR ELEVATING HDL CHOLESTEROL; ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1998-07-21 | — | — | US | disclosed |
| US-5756544-A | ADMINISTERING TO LOWER LEVELS OF LOW DENSITY LIPOPROTEINS AND TO RAISE THE LEVELS OF HIGH DENSITY LIPOPROTEINS | WARNER-LAMBERT COMPANY (US) | 1998-05-26 | — | — | US | disclosed |
| US-5750569-A | LOWERING PLASMA LIPIDS | WARNER-LAMBERT COMPANY (US) | 1998-05-12 | — | — | US | disclosed |
| EP-0820428-A1 | TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS | WARNER-LAMBERT COMPANY (US) | 1998-01-28 | — | — | EP | disclosed |
| US-5648387-A | Carboxyalkylethers, formulations, and treatment of vascular diseases | WARNER-LAMBERT COMPANY (US) | 1997-07-15 | — | — | US | disclosed |
| WO-1996030328-A1 | TERMINAL CARBOXY OR TETRAZOLE GROUPS CONTAINING DIALKYL ETHERS | WARNER-LAMBERT COMPANY (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402854-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKENE ETHERS | ELOVL3, DGKI, ELOVL5 | CYP4F2 77/4885CYP4A11 235/4885PKM 1082/4885 |
| US-10227285-B2 | Processes and intermediates for preparing alpha,omega-dicarboxylic acid-terminated dialkane ethers | DGKI, DGKA, SQLE | CYP4F2 129/4885CYP4A11 250/4885PKM 579/4885 |
| US-20200048181-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING alpha,omega-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS | DGKI, DGKA, SQLE | CYP4F2 129/4885CYP4A11 250/4885PKM 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.